Press Releases Keyword Search Year None2024202320222021202020192018201720162015201420132012 Apr 15, 2024 Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo Jan 25, 2024 Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress Jan 09, 2024 Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
Apr 15, 2024 Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Jan 25, 2024 Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
Jan 09, 2024 Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress